---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-038079"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-12-17T23:59:59+00:00"
generated_at: "2026-05-16T12:55:32.231879+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports positive Phase 1 results for WP1066 in pediatric malignant brain tumors

## Summary
- WP1066 showed no significant toxicity and determined maximum feasible dose in 10 children with high-grade glioma.
- Partial tumor response observed in a DIPG patient; anti-tumor immune responses demonstrated via STAT3 suppression.
- Results published in Journal of Clinical Investigation Insight; Phase 2 trial warranted based on findings.
- Compassionate use in 3 additional children with high-grade glioma also evaluated.
- Study funded by Peach Bowl LegACy Fund and CURE Childhood Cancer.

## SEC filing metadata
- accession: 0001437749-25-038079
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-12-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925038079/0001437749-25-038079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925038079/mbrx20251216_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-038079
- JSON: https://secwatch.observer/filing/0001437749-25-038079.json
- Plain text: https://secwatch.observer/filing/0001437749-25-038079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.